At Sanofi, our commitment to patients with rare blood disorders is personal. It’s what drives us year after year to keep looking for the next breakthrough and to meet the needs of people impacted by rare blood disorders.

Learn more about each treatment

INDICATION
QfitliaTM (fitusiran) is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children 12 years and older with hemophilia A or B with or without Factor VIII or IX inhibitors.
It is not known if Qfitlia is safe and effective in children younger than 12 years of age.
LEARN MORE
INDICATION
ALTUVIIIO® [antihemophilic factor (recombinant), Fc‑VWF‑XTEN fusion protein‑ehtl] is an injectable medicine that is used to control and reduce the number of bleeding episodes in people with hemophilia A (congenital Factor VIII deficiency).
Your healthcare provider may give you ALTUVIIIO when you have surgery.
LEARN MORE
INDICATION
ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with hemophilia B. Hemophilia B is also called congenital Factor IX deficiency. Your healthcare provider may give you ALPROLIX when you have surgery.
LEARN MORE
INDICATION
CABLIVI (caplacizumab-yhdp) is a prescription medicine used for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.
LEARN MORE
INDICATION
ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] is an injectable medicine that is used to help control and prevent bleeding in people with Hemophilia A (congenital Factor VIII deficiency). Your healthcare provider may give you ELOCTATE when you have surgery.
LEARN MORE

© 2025 Sanofi. All rights reserved.

Alprolix, Altuviiio, Cablivi, Eloctate, Qfitlia, and Sanofi are trademarks of Sanofi or an affiliate.

All other trademarks are the property of their respective owners.